down arrow

Traws Pharma, Inc.

  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US68232V8019
USD
2.36
0.2 (9.26%)

Dec 04

NAS

 Click here to see other stocks
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

2.052.40

52 Week

0.9719.44
Valuation
Technical
Day's Volume

CASH

438.15 k

Shareholding (Mar 2025)

FII

0.03%

Held by 8 FIIs

DII

81.91%

Held by 2 DIIs

Promoter

16.59%

How big is Traws Pharma, Inc.?

22-Jun-2025

As of Jun 18, Traws Pharma, Inc. has a market capitalization of 9.24 million and reported net sales of 0.24 million with a net profit of -34.60 million over the last four quarters. The company's shareholder's funds are -31.63 million, with total assets of 24.96 million.

Market Cap: As of Jun 18, Traws Pharma, Inc. has a market capitalization of 9.24 million, classified as a Micro Cap.<BR><BR>Recent Quarterly Performance: For the latest four quarters, Traws Pharma, Inc. reported net sales of 0.24 million and a net profit of -34.60 million.<BR><BR>Balance Sheet Snapshot: As of Dec 24, the company's shareholder's funds amounted to -31.63 million, while total assets were reported at 24.96 million.

Read More

What does Traws Pharma, Inc. do?

22-Jun-2025

Traws Pharma, Inc. is a clinical-stage biopharmaceutical company focused on developing small molecule drugs for cancer treatment. As of March 2025, it has a market cap of $9.24 million, with net sales of $0 million and a net profit of $15 million.

Overview: <BR>Traws Pharma, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule drug candidates to treat cancer within the Pharmaceuticals & Biotechnology industry.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 0 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 15 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 9.24 Million (Micro Cap) <BR><BR>Key Metrics: <BR>P/E: 0.00 <BR>Debt Equity: -2.66 <BR>Return on Equity: 939.05% <BR>Price to Book: 1.54 <BR><BR>Contact Details: <BR>Address: 375 Pheasant Run, NEWTOWN PA: 18940-3423 <BR>Tel: 1 267 7593680 <BR>Fax: 1 267 7593681 <BR>Website: https://www.onconova.com/

Read More

Who are in the management team of Traws Pharma, Inc.?

22-Jun-2025

As of March 2022, the management team of Traws Pharma, Inc. includes Mr. James Marino (Chairman), Dr. Steven Fruchtman (President and CEO), and Directors Dr. Henry Bienen, Dr. Jerome Groopman, Dr. Viren Mehta, Ms. Terri Shoemaker, and Mr. Jack Stover. They oversee the company's operations and strategic direction.

As of March 2022, the management team of Traws Pharma, Inc. includes the following individuals:<BR><BR>- Mr. James Marino, Chairman of the Board<BR>- Dr. Steven Fruchtman, President, Chief Executive Officer, and Director<BR>- Dr. Henry Bienen, Director<BR>- Dr. Jerome Groopman, Director<BR>- Dr. Viren Mehta, Director<BR>- Ms. Terri Shoemaker, Director<BR>- Mr. Jack Stover, Director<BR><BR>This team is responsible for overseeing the company's operations and strategic direction.

Read More

Is Traws Pharma, Inc. technically bullish or bearish?

20-Sep-2025

As of June 2, 2025, Traws Pharma, Inc. shows a mildly bearish trend, with daily moving averages indicating bearishness, while weekly and monthly indicators present mixed signals, and the stock has underperformed the S&P 500 with a year-to-date return of -76.80%.

As of 2 June 2025, the technical trend for Traws Pharma, Inc. has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by daily moving averages indicating a bearish trend, while weekly and monthly MACD and Dow Theory show mildly bullish signals. The Bollinger Bands present a mixed view with weekly bullishness and monthly mild bearishness. The stock has significantly underperformed the S&P 500 over multiple periods, with a year-to-date return of -76.80% compared to the S&P's 12.22%.

Read More

Is Traws Pharma, Inc. overvalued or undervalued?

25-Nov-2025

As of November 21, 2025, Traws Pharma, Inc. is considered very attractive due to its strong financial metrics, including a P/E ratio of 0, an EV to EBIT of 0.14, and a remarkable ROE of 939.05%, despite a challenging year with a YTD return of -72.64%, indicating significant potential for recovery compared to its peers.

As of 21 November 2025, Traws Pharma, Inc. has moved from an attractive to a very attractive valuation grade. The company appears to be undervalued, particularly when considering its strong financial metrics, including a P/E ratio of 0, an EV to EBIT of 0.14, and an impressive ROE of 939.05%. <BR><BR>When compared to peers, Traws Pharma's valuation ratios stand out; for instance, Catalyst Biosciences, Inc. has a P/E ratio of 110.04, indicating it is expensive relative to Traws. Additionally, Elutia, Inc. shows a risky profile with an EV to EBITDA of -5.54, further highlighting Traws Pharma's relative strength. Despite a challenging year with a YTD return of -72.64% compared to the S&P 500's 12.26%, Traws Pharma's three-year return of 191.72% suggests significant potential for recovery and growth.

Read More
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.

Dashboard
1

Poor long term growth as Net Sales has grown by an annual rate of 29.91% over the last 5 years

 
2

Positive results in Jun 25

3

With ROE of 939.05%, it has a does not qualify valuation with a 1.53 Price to Book Value

4

High Institutional Holdings at 48.49%

5

Underperformed the market in the last 1 year

stock-summaryMojo Parameters
Mojo Parameters
Stock DNA
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 13 Million (Micro Cap)

stock-summary
P/E

0.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

-1.58

stock-summary
Return on Equity

741.36%

stock-summary
Price to Book

1.59

Revenue and Profits:
Net Sales:
3 Million
(Quarterly Results - Jun 2025)
Net Profit:
-1 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
46.58%
0%
46.58%
6 Months
26.2%
0%
26.2%
1 Year
-54.44%
0%
-54.44%
2 Years
-86.5%
0%
-86.5%
3 Years
176.74%
0%
176.74%
4 Years
-96.42%
0%
-96.42%
5 Years
-98.04%
0%
-98.04%

Traws Pharma, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions
News

Is Traws Pharma, Inc. overvalued or undervalued?

As of 21 November 2025, the valuation grade for Traws Pharma, Inc. moved from attractive to very attractive. The company appears to be undervalued based on its financial metrics. Key ratios include a Price to Book Value of 1.53, an EV to EBIT of 0.14, and an impressive ROE of 939.05%. In comparison to its peers, Traws Pharma's P/E ratio of 0.2145 stands in stark contrast to Catalyst Biosciences, Inc., which has a P/E of 110.0436, indicating that Traws is significantly cheaper relative to its earnings potential. Additionally, while the industry faces challenges, Traws Pharma's strong ROCE of 496.52% highlights its efficient use of capital. Despite recent struggles, with a YTD return of -73.99% compared to the S&P 500's 12.26%, the long-term outlook remains promising, especially with a 3-year return of 156.67%....

Read More

Is Traws Pharma, Inc. overvalued or undervalued?

As of 14 November 2025, Traws Pharma, Inc. has moved from a very attractive to an attractive valuation grade. The company appears to be undervalued based on its valuation ratios, including a Price to Book Value of 1.53, an EV to EBIT of 0.14, and an impressive ROE of 939.05%. In comparison to peers, Catalyst Biosciences, Inc. is considered expensive with a P/E of 110.04, while Elutia, Inc. is classified as risky with a P/E of -2.83, highlighting Traws Pharma's relatively favorable position. Despite the recent stock performance showing a significant decline year-to-date of -76.58% compared to a 14.49% return for the S&P 500, the long-term perspective over three years reveals a strong return of 136.36%, which suggests potential recovery and growth ahead. Overall, Traws Pharma, Inc. is positioned as an undervalued opportunity in the pharmaceuticals and biotechnology sector....

Read More

Is Traws Pharma, Inc. overvalued or undervalued?

As of 14 November 2025, Traws Pharma, Inc. has moved from a very attractive to an attractive valuation grade. The company appears to be undervalued based on its current metrics, particularly with a Price to Book Value of 1.53, an EV to EBIT of 0.14, and an impressive ROE of 939.05%. When compared to peers, Traws Pharma's P/E ratio of 0.2145 stands in stark contrast to Catalyst Biosciences, Inc., which is considered expensive at a P/E of 110.0436, and Elutia, Inc., which has a risky valuation with a P/E of -2.8330. This suggests that Traws Pharma may offer a more favorable investment opportunity relative to its peers. Although specific return data is not available, the lack of negative returns compared to the S&P 500 reinforces the notion that Traws Pharma is positioned well in the market....

Read More
Announcements stock-summary
Icon
No announcement available
Corporate Actions stock-summary
Icon
No corporate action available
stock-summaryKey Factors
Quality key factors stock-summary
Factor
Value
Sales Growth (5y)
29.91%
EBIT Growth (5y)
-39.55%
EBIT to Interest (avg)
-21.25
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-2.66
Sales to Capital Employed (avg)
0.04
Tax Ratio
0
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
48.49%
ROCE (avg)
0
ROE (avg)
0
Valuation key factors
Factor
Value
P/E Ratio
0
Industry P/E
Price to Book Value
1.53
EV to EBIT
0.14
EV to EBITDA
0.14
EV to Capital Employed
0.68
EV to Sales
-6.76
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
496.52%
ROE (Latest)
939.05%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Mildly Bearish
Moving Averages
Bullish (Daily)
KST
Bullish
Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bullish
No Trend
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Mar 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Strategic Entities

Domestic Funds

Held in 2 Schemes (1.47%)

Foreign Institutions

Held by 8 Foreign Institutions (0.03%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 2,600.00% vs 0.00% in Jun 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in quarter ended Jun 2025 is 99.51% vs -2,830.95% in Jun 2024",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Jun'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "2.70",
          "val2": "0.10",
          "chgp": "2,600.00%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-1.20",
          "val2": "-5.90",
          "chgp": "79.66%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.10",
          "val2": "-117.50",
          "chgp": "100.09%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-0.60",
          "val2": "-123.10",
          "chgp": "99.51%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-457.00%",
          "val2": "-103,228.10%",
          "chgp": "10,277.11%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023",
        "dir": 0
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is -189.42% vs 0.53% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "0.20",
          "val2": "0.20",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-49.30",
          "val2": "-20.30",
          "chgp": "-142.86%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "-117.50",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-54.70",
          "val2": "-18.90",
          "chgp": "-189.42%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-218,354.00%",
          "val2": "-89,814.20%",
          "chgp": "-12,853.98%",
          "chgp_class": "negative"
        }
      ]
    }
  }
]
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoYstock-summary
Jun'25
Jun'24
Change(%)
Net Sales
2.70
0.10
2,600.00%
Operating Profit (PBDIT) excl Other Income
-1.20
-5.90
79.66%
Interest
0.00
0.00
Exceptional Items
0.10
-117.50
100.09%
Consolidate Net Profit
-0.60
-123.10
99.51%
Operating Profit Margin (Excl OI)
-457.00%
-103,228.10%
10,277.11%
USD in Million.
stock-summary Compare with Peers
Direction Arrows
Net Sales

YoY Growth in quarter ended Jun 2025 is 2,600.00% vs 0.00% in Jun 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in quarter ended Jun 2025 is 99.51% vs -2,830.95% in Jun 2024

All Quarterly Resultsstock-summary
Annual Results Snapshot (Consolidated) - Dec'24stock-summary
Dec'24
Dec'23
Change(%)
Net Sales
0.20
0.20
Operating Profit (PBDIT) excl Other Income
-49.30
-20.30
-142.86%
Interest
0.00
0.00
Exceptional Items
-117.50
0.00
Consolidate Net Profit
-54.70
-18.90
-189.42%
Operating Profit Margin (Excl OI)
-218,354.00%
-89,814.20%
-12,853.98%
USD in Million.
stock-summary Compare with Peers
Net Sales

YoY Growth in year ended Dec 2024 is 0.00% vs 0.00% in Dec 2023

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2024 is -189.42% vs 0.53% in Dec 2023

All Annual Resultsstock-summary
stock-summaryCompany CV
About Traws Pharma, Inc. stock-summary
stock-summary
Traws Pharma, Inc.
Pharmaceuticals & Biotechnology
Onconova Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company operates through the identification and development of oncology therapeutics segment. It is focused on discovering and developing small molecule drug candidates to treat cancer. The Company has created a targeted anti-cancer agents designed to work against specific cellular pathways that are important to cancer cells. It has over three clinical-stage product candidates and various preclinical programs that target kinases, cellular metabolism or cell division in preclinical development. The Company's lead product candidate, rigosertib, is being tested in both intravenous (IV) and oral formulations as a single agent, and the oral formulation is also being tested in combination with azacitidine, in clinical trials for patients with myelodysplastic syndromes (MDS), and related cancers. Its other product candidates include Briciclib and Recilisib.
Company Coordinates stock-summary
Company Details
375 Pheasant Run , NEWTOWN PA : 18940-3423
stock-summary
Tel: 1 267 7593680
stock-summary
https://www.onconova.com/
stock-summary
Registrar Details
Stock List
ABCDEFGHIJKLMNOPQRSTUVWXYZOther
Footer Logo
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
Market
Webinars
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."